Cited 21 times in
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2018-05-10T06:36:27Z | - |
dc.date.available | 2018-05-10T06:36:27Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/158291 | - |
dc.description.abstract | Bacjground : To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded access program (LEAP). Methods : LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast cancer patients with progression after an anthracycline, taxane, and trastuzumab were eligible. Patients received capecitabine 2000 mg/m(2) daily in two divided doses, days 1-14, every 21 days and lapatinib 1250 mg once daily. Results : Among 186 patients enrolled in 6 Korean centers, 58 had BM. Progression-free survival (PFS) was 18.7 weeks in patients with BM and 19.4 weeks without BM (P = 0.88). In patients with BM, brain response was synchronized with systemic responses (P = 0.0001). Overall survival (OS) was 48.9 weeks in patients with BM and 64.6 weeks without BM (P = 0.23). Multivariable analysis found hormone receptor positivity (P = 0.003) and clinical benefit rate (CBR) of combined systemic and brain disease (P < 0.0001) significantly associated with prolonged brain PFS, and CBR of combined systemic and brain disease (P = 0.03) and longer trastuzumab use (P = 0.047) associated with prolonged OS in patients with BM; prior capecitabine did not affect PFS or OS in patients with BM. Conclusion : Lapatinib plus capecitabine is equally effective in patients with or without BM. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Brain Neoplasms/drug therapy* | - |
dc.subject.MESH | Brain Neoplasms/mortality | - |
dc.subject.MESH | Brain Neoplasms/secondary* | - |
dc.subject.MESH | Breast Neoplasms/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/pathology* | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Quinazolines/administration & dosage | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism* | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jungsil Ro | - |
dc.contributor.googleauthor | Sohee Park | - |
dc.contributor.googleauthor | Sung- Bae Kim | - |
dc.contributor.googleauthor | Tae You Kim | - |
dc.contributor.googleauthor | Young Hyuk Im | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Joo Seop Chung | - |
dc.contributor.googleauthor | Hanlim Moon | - |
dc.contributor.googleauthor | Sergio Santillana | - |
dc.identifier.doi | 10.1186/1471-2407-12-322 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 22839200 | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 322 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.12 : 322, 2012 | - |
dc.identifier.rimsid | 40667 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.